scispace - formally typeset
B

Bradley S. Marino

Researcher at Northwestern University

Publications -  223
Citations -  10570

Bradley S. Marino is an academic researcher from Northwestern University. The author has contributed to research in topics: Heart disease & Population. The author has an hindex of 46, co-authored 199 publications receiving 8681 citations. Previous affiliations of Bradley S. Marino include Harvard University & Children's Hospital of Philadelphia.

Papers
More filters
Journal ArticleDOI

Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association.

TL;DR: A CHD algorithm for surveillance, screening, evaluation, reevaluation, and management of developmental disorder or disability has been constructed to serve as a supplement to the 2006 American Academy of Pediatrics statement on developmental surveillance and screening.
Journal ArticleDOI

Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association.

TL;DR: There is a clear need for consensus on how best to follow up patients with Fontan circulation and to treat their complications, and a proposed surveillance testing toolkit provides recommendations for a range of acceptable approaches to follow-up care.
Journal ArticleDOI

Brain in Congenital Heart Disease Across the Lifespan: The Cumulative Burden of Injury.

TL;DR: Against the backdrop of shifting demographics, risk factors for brain injury in the CHD population are cumulative and synergistic and a growing population of CHD can be expected to require support services.
Journal ArticleDOI

Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: A randomized, double-blind, placebo-controlled, crossover trial

TL;DR: In this article, a double-blind, placebo-controlled, crossover trial was conducted in children and young adults after the Fontan operation and subjects were randomized to receive placebo or sildenafil (20 mg three times daily) for 6 weeks.